EIF2S1

Eukaryotic translation initiation factor 2 subunit 1 · P05198 · EIF2S1 on Sugi Atlas →

2,337 patent compounds predicted against EIF2S1, 980 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20541830 SCHEMBL20541830 1.00 19/20
SCHEMBL23044120 SCHEMBL23044120 1.00 19/20
SCHEMBL23044133 SCHEMBL23044133 1.00 19/20
SCHEMBL23044144 SCHEMBL23044144 1.00 19/20
SCHEMBL23044167 SCHEMBL23044167 1.00 19/20
SCHEMBL23044202 SCHEMBL23044202 1.00 19/20
SCHEMBL23044205 SCHEMBL23044205 1.00 19/20
SCHEMBL23044221 SCHEMBL23044221 1.00 19/20
SCHEMBL23044252 SCHEMBL23044252 1.00 19/20
SCHEMBL23044265 SCHEMBL23044265 1.00 19/20
SCHEMBL23044270 SCHEMBL23044270 1.00 19/20
SCHEMBL23044272 SCHEMBL23044272 1.00 19/20
SCHEMBL23044273 SCHEMBL23044273 1.00 19/20
SCHEMBL23044329 SCHEMBL23044329 1.00 19/20
SCHEMBL23044339 SCHEMBL23044339 1.00 19/20
SCHEMBL23044400 SCHEMBL23044400 1.00 19/20
SCHEMBL23044424 SCHEMBL23044424 1.00 19/20
SCHEMBL23044519 SCHEMBL23044519 1.00 19/20
SCHEMBL23044580 SCHEMBL23044580 1.00 19/20
SCHEMBL23044599 SCHEMBL23044599 1.00 19/20

Clinical trials — most relevant to EIF2S1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
The Effects of Whey vs. Collagen on MPS nanCOMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
miRNA as a Growth Plate Marker After GH nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF2S1 binder may also engage these)

ProteinNameSimilarity
P68102 1.000 P68102 →
Q6ZWX6 1.000 Q6ZWX6 →
Q5ZLX2 1.000 Q5ZLX2 →
Q5R493 1.000 Q5R493 →
Q7ZTK4 0.999 Q7ZTK4 →
P68101 0.998 P68101 →
P20460 0.997 P20460 →
P56286 0.997 P56286 →
P20459 0.996 P20459 →
Q6GL89 0.993 Q6GL89 →
P41374 0.989 P41374 →
Q869N9 0.989 Q869N9 →
P37202 0.976 P37202 →
Q9FLE4 0.976 Q9FLE4 →
F4JWP9 0.976 F4JWP9 →
Q9LNC5 0.975 Q9LNC5 →
A1D5Z0 0.974 A1D5Z0 →
A0A509AJP9 0.974 A0A509AJP9 →
Q23680 0.974 Q23680 →
C5JRK2 0.973 C5JRK2 →
Q6BIJ0 0.973 Q6BIJ0 →
Q9CSH3 0.973 Q9CSH3 →
A8XFM8 0.973 A8XFM8 →
B0XZZ2 0.973 B0XZZ2 →
Q9ZVT7 0.973 Q9ZVT7 →
O74407 0.973 O74407 →
Q03330 0.973 Q03330 →
A5B4D2 0.973 A5B4D2 →
O13794 0.973 O13794 →
C5GRI9 0.973 C5GRI9 →